Pancreatic Cancer Clinical Trials

One of the unique benefits of being a University of Michigan patient is access to the latest and most promising therapies for cancer. Our doctors are working hard to find cures, but they can't do it alone. Patients play a vital role by participating in research studies -- also known as clinical trials.

Pancreatic Adenocarcinoma Trials:


2014.025 A Phase 3, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Aloine as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Pre-Surgery/Neoadjuvant/Borderline Resectable

2011.007 A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine with Concurrent IMRT in Patients with Borderline Resectable Pancreatic Cancer

Locally Advanced/Unresectable

2013.094 A Dose Escalation Trial of the Wee1 Inhibitor MK1775, in Combination with Gemcitabine (+Radiation) for Patients with Unresectable Adenocarcinoma of the Pancreas

2013.095 Phase 2 Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma with BRCA/ PALB2 Mutation and a Phase 2 Study of Veliparib in Previously Treated Pancreas Adenocarcinoma

2011.105 A Phase I Trial of Cabozantinib (XL 184) and Gemcitabine in Advanced Pancreatic Cancer


2011.055 A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

2008.034 A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response

Pancreatice Neuroendocrine Carcinoma Trials


If you would like to speak to someone about this trial -- or other trials available at the University of Michigan Health System -- please contact the Cancer AnswerLine™ at 800-865-1125.